Abstract:The equilibrium between histone acetylation and deacetylation plays an important role in cancer initiation and progression. The histone deacetylases (HDACs) are a class of key regulators of gene expression that enzymatically remove an acetyl moiety from acetylated lysine ε-amino groups on histone tails. Therefore, HDAC inhibitors have recently emerged as a promising strategy for cancer therapy and several pan-HDAC inhibitors have globally been approved for clinical use. In the present study, we designed and synthesized a series of substituted indole-based hydroxamic acid derivatives that exhibited potent anti-proliferative activities in various tumor cell lines. Among the compounds tested, compound 4o, was found to be among the most potent in the inhibition of HDAC1 (half maximal inhibitory concentration, IC50 = 1.16 nM) and HDAC6 (IC50 = 2.30 nM). It also exhibited excellent in vitro anti-tumor proliferation activity. Additionally, compound 4o effectively increased the acetylation of histone H3 in a dose-dependent manner and inhibited cell proliferation by inducing cell cycle arrest and apoptosis. Moreover, compound 4o remarkably blocked colony formation in HCT116 cancer cells. Based on its favorable in vitro profile, compound 4o was further evaluated in an HCT116 xenograft mouse model, in which it demonstrated better in vivo efficacy than the clinically used HDAC inhibitor, suberanilohydroxamic acid. Interestingly, compound 4k was found to have a preference for the inhibition of HDAC6, with IC50 values of 115.20 and 5.29 nM against HDAC1 and HDAC6, respectively.

Synthesis and Antitumor Activity of Novel Diaryl Ether Hydroxamic Acids Derivatives As Potential HDAC Inhibitors

Synthesis, Biological Evaluation and Molecular Docking Studies of 3-(1,3-diphenyl-1h-pyrazol-4-yl)-n-phenylacrylamide Derivatives As Inhibitors of HDAC Activity.

Synthesis and Biological Evaluation of Thiophene-Based Hydroxamate Derivatives As HDACis with Antitumor Activities

Design, Synthesis and Biological Evaluation of Novel Compounds with Conjugated Structure As Anti-Tumor Agents.

Design, synthesis and antitumor activity evaluation of novel HDAC inhibitors with tetrahydrobenzothiazole as the skeleton

Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.

Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors

Development of Hydroxamate-Based Histone Deacetylase Inhibitors Containing 1,2,4-Oxadiazole Moiety Core with Antitumor Activities.

Design, synthesis and bioevaluation of novel N-heterocyclic hydroxamic acids as histone deacetylase inhibitors and their antitumor activity study

Design, Synthesis, And Activity Of Hdac Inhibitors With A N-Formyl Hydroxylamine Head Group

Novel hydroxamic acids incorporating 1-((1H-1,2,3-Triazol-4-yl)methyl)-3-hydroxyimino-indolin-2-ones: synthesis, biological evaluation, and SAR analysis

Design and optimization of novel Tetrahydro-β-carboline-based HDAC inhibitors with potent activities against tumor cell growth and metastasis

[Design, Synthesis, and Biological Activities of Histone Deacetylase Inhibitors with Diketo Ester As Zinc Binding Group].

Design, Synthesis and Anticancer Evaluation of Acridine Hydroxamic Acid Derivatives As Dual Topo and HDAC Inhibitors.

Synthesis and anticancer activity of novel histone deacetylase inhibitors that inhibit autophagy and induce apoptosis

Design, Synthesis and Anticancer Potential of NSC-319745 Hydroxamic Acid Derivatives As DNMT and HDAC Inhibitors

Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.

Synthesis, Evaluation and Molecular Modeling of Cyclic Tetrapeptide Histone Deacetylase Inhibitors As Anticancer Agents.

Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Discovery of Chiral 1,4-Diarylazetidin-2-one-Based Hydroxamic Acid Derivatives as Novel Tubulin Polymerization Inhibitors with Histone Deacetylase Inhibitory Activity